SE0100011D0 - Virus vaccine formulation - Google Patents

Virus vaccine formulation

Info

Publication number
SE0100011D0
SE0100011D0 SE0100011A SE0100011A SE0100011D0 SE 0100011 D0 SE0100011 D0 SE 0100011D0 SE 0100011 A SE0100011 A SE 0100011A SE 0100011 A SE0100011 A SE 0100011A SE 0100011 D0 SE0100011 D0 SE 0100011D0
Authority
SE
Sweden
Prior art keywords
formulation
vaccine formulation
adjuvant
protein
virus vaccine
Prior art date
Application number
SE0100011A
Other languages
Swedish (sv)
Inventor
Ulf Schroeder
De Cavalho Nicacio Christ Afua
Aake Lundkvist
Original Assignee
Eurocine Ab Karolinska Inst Sc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eurocine Ab Karolinska Inst Sc filed Critical Eurocine Ab Karolinska Inst Sc
Priority to SE0100011A priority Critical patent/SE0100011D0/en
Publication of SE0100011D0 publication Critical patent/SE0100011D0/en
Priority to PCT/SE2001/002788 priority patent/WO2002053183A1/en

Links

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)

Abstract

A vaccine formulation against a microorganism is disclosed. The formulation comprises as adjuvant, one or more substances selected from a) monoglyceride preparations having at least 80% monoglyceride content and b) fatty acids of the general formula CH3-(CH2)n-COOH where "n" may be varied between 4 and 22, and where the acyl chain may contain one or more unsaturated bonds, and as immunizing component, an immunogenic product consisting of antigenically active N protein from a Hantavirus, the formulation may comprise, as adjuvant, a mixture of mono-oleic and oleic acid, and possibly soybean oil, and, as immunizing component, the N protein from a Hanta virus.
SE0100011A 2001-01-03 2001-01-03 Virus vaccine formulation SE0100011D0 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SE0100011A SE0100011D0 (en) 2001-01-03 2001-01-03 Virus vaccine formulation
PCT/SE2001/002788 WO2002053183A1 (en) 2001-01-03 2001-12-14 Hantavirus vaccin with adjuvant

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE0100011A SE0100011D0 (en) 2001-01-03 2001-01-03 Virus vaccine formulation

Publications (1)

Publication Number Publication Date
SE0100011D0 true SE0100011D0 (en) 2001-01-03

Family

ID=20282535

Family Applications (1)

Application Number Title Priority Date Filing Date
SE0100011A SE0100011D0 (en) 2001-01-03 2001-01-03 Virus vaccine formulation

Country Status (2)

Country Link
SE (1) SE0100011D0 (en)
WO (1) WO2002053183A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2469491A1 (en) 2001-12-12 2003-06-19 Kerrie Setiawan Composition for viral preservation
AU2002366653B2 (en) * 2001-12-12 2008-05-15 Commonwealth Scientific And Industrial Research Organisation Composition for the preservation of viruses
AU2003292136A1 (en) * 2002-11-26 2004-06-18 Eurocine Ab Vaccines against viruses with cationic substances as adjuvants
CN110548136A (en) * 2018-05-30 2019-12-10 王美亮 Hantavirus long peptide vaccine

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR900007952B1 (en) * 1988-11-18 1990-10-23 주식회사 녹십자 Novel hantaan virus and method for preparation of its vaccine
US5916754A (en) * 1995-02-17 1999-06-29 The United States Of America As Represented By The Department Of Health And Human Services Bayou hantavirus and related methods
SE9600436D0 (en) * 1996-02-06 1996-02-06 Aake Lundkvist Vaccine against hantavirus
SE9602280D0 (en) * 1996-06-10 1996-06-10 Pharmatrix Ab Immune-stimulating lipid formulation

Also Published As

Publication number Publication date
WO2002053183A1 (en) 2002-07-11

Similar Documents

Publication Publication Date Title
MD1586G2 (en) Induction of the cytitoxic T-lymphocytic response
BR0107972A (en) Use of a hiv tat, hiv nef, or hiv tat protein or polynucleotide attached to a hiv nef protein or polynucleotide (nef-tat), and a hiv gp120 protein or polynucleotide, method for immunizing a hiv human being against hiv, and vaccine composition for human use
DE60127457D1 (en) FIBRATE STATIN COMBINES WITH REDUCED EFFECT ON THE FOOD RECEIPT
HUT69784A (en) Induction of cytotoxic t-lymphocyte responses
WO2002000266A3 (en) A method of treating and preventing infectious diseases
CY1111872T1 (en) COMPOSITIONS FOR HYPOTHESIS (PROSTAGLANDIN) AND TIMOLOLIS - RELATED METHODS OF USE
HUP0401606A2 (en) West nile vaccine
ATE306938T1 (en) USE OF CPG AS AN ADJUVANT FOR HIV VACCINE
SE9602280D0 (en) Immune-stimulating lipid formulation
WO2000047224A3 (en) Vaccine formulation comprising monoglycerides or fatty acids as adjuvant
UY26303A1 (en) PHARMACEUTICAL COMPOSITIONS FOR ORAL AND TOPICAL ADMINISTRATION
ATE458496T1 (en) HIV VACCINES AND METHODS OF APPLICATION
FI972054A (en) Immunogenic compositions
WO2000047225A3 (en) Tuberculosis vaccine formulation comprising monoglycerides or fatty acids as adjuvant
CA2057828A1 (en) Cytotoxic t lymphocyte-inducing lipopeptides and use as vaccines
SE0100011D0 (en) Virus vaccine formulation
BR0212467A (en) Procedure for the preparation of unsaturated hydroxy fatty acids and their esters, their use in pharmaceutical and / or cosmetic preparations
WO2005053669A8 (en) Use of omega-3 polyunsaturated fatty acids for sleep apnoea
SE9903915L (en) Cholesterol lowering and blood fat lowering composition
WO2002017961A1 (en) Vaccine preparation containing fatty acid as component
BRPI0414073A (en) method for inducing an immune response against rotavirus infection from a rotavirus serotype, and use of an attenuated rotavirus strain of a serotype
MY137709A (en) Method for obtaining antigenic structures of high cross reactivity and their use in formulations
ATE146175T1 (en) NEW CARDIOPROTECTION ACTIVE INGREDIENTS
RU2000110788A (en) METHOD OF OBTAINING AN ANALOGUES OF TAXOL WITH ANTITUMOR ACTIVITY
WO2002074332A3 (en) Method to enhance the immunogenicity of an antigen